Rheumatoid Arthritis Before and Beyond the Joint: Early Recognition, Targeted Treatment, and Primary Care Co-Management.

Abstract

Rheumatoid arthritis (RA) is increasingly recognized as a systemic disease that evolves from genetic susceptibility and mucosal immune dysregulation to systemic autoimmunity, arthralgia, subclinical inflammation and ultimately, in a subset of patients, to clinically apparent arthritis. This review aims to provide primary care clinicians with a practical framework for recognizing suspected early RA, facilitating timely rheumatology referral, and supporting comorbidity co-management. It also highlights current treatment concepts and emerging evidence on precision diagnosis and therapy. The disease-continuum model has created opportunities for earlier identification of at-risk individuals and stage-adapted interventions, although preventive strategies remain investigational. Early diagnosis remains challenging, especially in seronegative RA. Prompt disease-modifying antirheumatic drug initiation, within a treat-to-target framework, has improved outcomes. However, many patients continue to experience flares, and remission is not universal. Precision treatment selection is evolving, but not yet routine. Importantly, RA extends beyond joint inflammation: cardiovascular disease and RA-associated interstitial lung disease are major drivers of morbidity and mortality. Shared primary care-rheumatology management should address cardiovascular risk, RA-ILD risk, vaccination, bone protection, perioperative planning and treatment safety. Overall, RA management is shifting from reactive treatment of clinically apparent arthritis toward earlier recognition, tighter disease control and personalized comprehensive care.